Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 8, 2025

Rio2 Expands in Latin America With the Acquisition of the Producing Condestable Mine

View original at globenewswire.com
Rio2 Expands in Latin America With the Acquisition of the Producing Condestable Mine Positions Rio2 as a Diversified Latin American Gold Miner with Copper Exposure Concurrent C$140 Million Bought Deal Equity Financing to Support the Acquisition NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATI…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Condestable has 10+ years reserve life and demonstrates year-over-year reserve/resource growth

    80% confidence

  • Pro forma Rio2 will generate approximately US$330M in annual EBITDA

    80% confidence

  • Condestable mine will produce average annual EBITDA of approximately US$110M at consensus prices or US$145M at spot prices for 2026-2030

    80% confidence

  • Post-Fenix Phase 2 (2031+) total production potential is approximately 380,000 oz gold equivalent with gold contributing over 80% of revenue at long-term consensus prices

    80% confidence

  • Near-term production (2027-2028) will be approximately 180,000 oz gold equivalent with copper representing less than 30% of revenue at spot prices

    80% confidence

  • Copper is trading at historic lows relative to gold, making this an opportune time for copper acquisition

    80% confidence

  • Condestable is one of only two operating IOCG mines in Peru

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com